Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study (vol 41, pg 3523, 2023)

被引：0
|
作者：
Cartron
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 25期
关键词：
D O I：
10.1200/JCO.23.01377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4187 / 4187
页数：1
相关论文
共 50 条
  • [41] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Lueck, Hans-Joachim
    Du Bois, Andreas
    Loibl, Sibylle
    Schrader, Iris
    Huober, Jens
    Heilmann, Volker
    Beckmann, Matthias
    Staehler, Ann
    Jackisch, Christian
    Hubalek, Michael
    Richter, Barbara
    Stickeler, Elmar
    Eidtmann, Holger
    Thomssen, Christoph
    Untch, Michael
    Wollschlaeger, Kerstin
    Schuster, Tibor
    von Minckwitz, Gunter
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 779 - 787
  • [42] A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models.
    Press, Oliver W.
    Unger, Joseph M.
    LeBlanc, Michael Leo
    Rimsza, Lisa M.
    Friedberg, Jonathan W.
    Czuczman, Myron Stefan
    Kaminski, Mark Stefan
    Braziel, Rita M.
    Spier, Catherine M.
    Maloney, David G.
    Cheson, Bruce D.
    Miller, Thomas P.
    Fisher, Richard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
    Morschhauser, Franck
    Radford, John
    Van Hoof, Achiel
    Botto, Barbara
    Rohatiner, Ama Z. S.
    Salles, Gilles
    Soubeyran, Pierre
    Tilly, Herve
    Bischof-Delaloye, Angelika
    van Putten, Wim L. J.
    Kylstra, Jelle W.
    Hagenbeek, Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (16) : 1977 - +
  • [44] Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3767 - 3767
  • [45] Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)
    Davies, Andrew
    Merli, Francesco
    Mihaljevik, Biljana
    Siritanaratkul, Noppadol
    Solal-Celigny, Philippe
    Boehnke, Axel
    Berge, Claude
    McIntyre, Christine
    Barrett, Martin
    Macdonald, David
    BLOOD, 2012, 120 (21)
  • [46] Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study)
    Dai, Yu-Hong
    Yu, Xiong-Jie
    Xu, Hui-Ting
    Zhuang, Liang
    Zhang, Ming-Sheng
    Zou, Yan-Mei
    Fu, Qiang
    Qiu, Hong
    Yuan, Xiang-Lin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [47] Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).
    Wang, Michael
    Jurczak, Wojciech
    Jerkeman, Mats
    Trotman, Judith
    Zinzani, Pier Luigi
    Walewski, Jan Andrzej
    Zhu, Jun
    Spurgeon, Stephen
    Goy, Andre
    Hamlin, Paul A.
    Belada, David
    Ozcan, Muhit
    Storring, John
    Lewis, David John
    Rivas, Jose Angel Hernandez
    Henninger, Todd
    Deshpande, Sanjay
    Qin, Rui
    Le Gouill, Steven
    Dreyling, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [48] First-line treatment with single agent rituximab, followed by maintenance rituximab plus anti-idiotype Id-KLH active immunotherapy vaccine (FavId) in patients (pts) with low-grade non-Hodgkin lymphoma (NHL): Preliminary results of a phase II trial
    Raefsky, E.
    Greco, F. A.
    Spigel, D. R.
    Litchy, S.
    Gian, V.
    Bender, J.
    Hainsworth, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study (vol 81, pg 17, 2017)
    Chau, Ian
    Peck-Radosavljevic, Markus
    Borg, Christophe
    Malfertheiner, Peter
    Seitz, Jean Francois
    Park, Joon Oh
    Ryoo, Baek-Yeol
    Yen, Chia-Jui
    Kudo, Masatoshi
    Poon, Ronnie
    Pastorelli, Davide
    Blanc, Jean-Frederic
    Chung, Hyun Cheol
    Baron, Ari D.
    Okusaka, Takuji
    Bowman, L.
    Cui, Zhanglin Lin
    Girvan, Allicia C.
    Abada, Paolo B.
    Yang, Ling
    Zhu, Andrew X.
    EUROPEAN JOURNAL OF CANCER, 2018, 100 : 135 - 136
  • [50] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015)
    Yardley, Denise A.
    Brufsky, Adam
    Coleman, Robert E.
    Conte, Pierfranco F.
    Cortes, Javier
    Glueck, Stefan
    Nabholtz, Jean-Mark A.
    O'Shaughnessy, Joyce
    Beck, Robert M.
    Ko, Amy
    Renschler, Markus F.
    Barton, Debora
    Harbeck, Nadia
    TRIALS, 2016, 17
12345